These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Stability and pre-formulation development of a plant-produced anthrax vaccine candidate. Jones RM; Burke M; Dubose D; Chichester JA; Manceva S; Horsey A; Streatfield SJ; Breit J; Yusibov V Vaccine; 2017 Oct; 35(41):5463-5470. PubMed ID: 28117174 [TBL] [Abstract][Full Text] [Related]
24. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(45):1024-6. PubMed ID: 12458919 [TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of a subunit vaccine against Bacillus anthracis. Chichester JA; Musiychuk K; de la Rosa P; Horsey A; Stevenson N; Ugulava N; Rabindran S; Palmer GA; Mett V; Yusibov V Vaccine; 2007 Apr; 25(16):3111-4. PubMed ID: 17280756 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: preclinical evaluation in rabbits and Rhesus monkeys. Chawla A; Midha S; Bhatnagar R Biotechnol J; 2009 Mar; 4(3):391-9. PubMed ID: 19296443 [TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model. Ndumnego OC; Koehler SM; Crafford JE; Beyer W; van Heerden H Sci Rep; 2018 Nov; 8(1):16937. PubMed ID: 30446695 [TBL] [Abstract][Full Text] [Related]
28. Results of a safety and immunogenicity study of an early-stage investigational rPA102 vaccine as compared to the FDA licensed anthrax vaccine (anthrax vaccine adsorbed (AVA. BioThrax)). Hannesschlager JR Vaccine; 2007 Apr; 25(17):3247. PubMed ID: 17234308 [No Abstract] [Full Text] [Related]
29. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Little SF; Ivins BE; Webster WM; Fellows PF; Pitt ML; Norris SL; Andrews GP Vaccine; 2006 Mar; 24(14):2530-6. PubMed ID: 16417950 [TBL] [Abstract][Full Text] [Related]
30. Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism. Bouzianas DG Expert Rev Anti Infect Ther; 2007 Aug; 5(4):665-84. PubMed ID: 17678429 [TBL] [Abstract][Full Text] [Related]
31. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine. Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051 [TBL] [Abstract][Full Text] [Related]
32. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
34. Is new always better than old?: The development of human vaccines for anthrax. Baillie LW Hum Vaccin; 2009 Dec; 5(12):806-16. PubMed ID: 19786839 [TBL] [Abstract][Full Text] [Related]
35. Advances in the development of next-generation anthrax vaccines. Friedlander AM; Little SF Vaccine; 2009 Nov; 27 Suppl 4():D28-32. PubMed ID: 19837282 [TBL] [Abstract][Full Text] [Related]
36. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine. Lininger LA; Cullum ME; Lyles MB; Bienek DR Vaccine; 2007 Feb; 25(9):1619-25. PubMed ID: 17150286 [TBL] [Abstract][Full Text] [Related]